BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
Active, not recruiting
- Conditions
- Multiple Sclerosis (MS)
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4
- Registration Number
- NCT06053749
- Locations
- 🇸🇪
Many locations, Multiple Locations, Sweden
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 1
Recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 232
- Registration Number
- NCT06052306
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Minnesota Medical Center, Minneapolis, Minnesota, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)
Phase 1
Active, not recruiting
- Conditions
- Pulmonary Hypertension Due to Left Heart Disease
- Interventions
- Drug: BAY2701250 IVDrug: BAY2701250 SCDrug: Placebo IVDrug: Placebo SC
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 78
- Registration Number
- NCT06048120
- Locations
- 🇩🇪
NUVISAN GmbH Neu-Ulm, Neu-Ulm, Bayern, Germany
An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2326
- Registration Number
- NCT06029010
- Locations
- 🇺🇸
Many Locations, Multiple Locations, New Jersey, United States
An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings
Completed
- Conditions
- Non-metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1375
- Registration Number
- NCT06013475
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer
Active, not recruiting
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Interventions
- Other: No Intervention
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 100
- Registration Number
- NCT06010914
- Locations
- 🇯🇵
Many Locations, Multiple Locations, Japan
The VERIFY Study: An Observational Study Called VERIFY to Learn More About the Use of Vericiguat in People With Chronic Heart Failure With Reduced Ejection Fraction
Completed
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1391
- Registration Number
- NCT05974189
- Locations
- 🇩🇪
Bayer, Berlin, Germany
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)
Phase 3
Completed
- Conditions
- Contrast Enhancement in Magnetic Resonance ImagingNon-central Nervous System Pathology
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 404
- Registration Number
- NCT05915728
- Locations
- 🇨🇿
Fakultni nemocnice Plzen - Lochotin, Plzen, Czechia
🇦🇷Sanatorio Allende | Departamento de Investigación Clínica, Córdoba, Argentina
🇫🇷Hôpital Bichat Claude Bernard - Service de radiologie, Paris, France
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems
Phase 3
Completed
- Conditions
- Central Nervous System PathologyContrast Enhancement in Magnetic Resonance Imaging
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 303
- Registration Number
- NCT05915702
- Locations
- 🇨🇿
Fakultni nemocnice Plzen - Lochotin, Plzen, Czechia
🇭🇺Szent Damjan Gorogkatolikus Korhaz, Kisvarda, Hungary
🇭🇺Idegsebeszeti Klinika, Pecs, Hungary
An Observational Study to Learn More How Chronic Kidney Disease Gradually Changes Over Time in Adults Using Electronic Healthcare Records (CKD Natural History Study)
Completed
- Conditions
- Chronic Kidney Disease
- Interventions
- Other: No Intervention
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 969394
- Registration Number
- NCT05914259
- Locations
- 🇩🇪
Bayer, Wuppertal, Germany
© Copyright 2025. All Rights Reserved by MedPath